Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625949 | 0.93 | ACKR3 (0.41) | NOTUMACKR3CHRM3LCKPDE3B | |
| SCHEMBL1625064 | 0.91 | TP53 (0.41) | NOTUMCHRM3TSHRBCL9CTNNB1 | |
| SCHEMBL1625651 | 0.88 | HSD17B10 (0.41) | HSD17B10NOTUMGPBAR1NAMPTSMN1; SMN2 | |
| SCHEMBL1625656 | 0.88 | HSD17B10 (0.41) | HSD17B10NOTUMGPBAR1NAMPTSMN1; SMN2 | |
| SCHEMBL1625655 | 0.86 | SMN1; SMN2 (0.46) | HSD17B10GPBAR1SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL1284004 | 0.86 | SMN1; SMN2 (0.46) | HSD17B10GPBAR1SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL1625628 | 0.84 | SMN1; SMN2 (0.47) | HSD17B10GPBAR1SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL1624548 | 0.82 | NOTUM (0.47) | HSD17B10NOTUM | |
| SCHEMBL15163517 | 0.82 | NOTUM (0.47) | HSD17B10NOTUM | |
| Hydrochloric Acid SCHEMBL1283752 | 0.81 | NOTUM (0.46) | HSD17B10NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | HSD17B10 3156/4885NOTUM 4463/4885ACKR3 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.